BIOPHTA

About the deal

Paris, June 3, 2024. BIOPHTA, a preclinical biotech company developing a game-changing technology for the treatment of eye diseases, has just closed a € 6.5 million Seed round to bring its patented technology to clinical development. This funding round was led by leading European VCs – UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), Elaia and GO Capital – as well as one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.

With a first program in the treatment of Glaucoma (Phase 1 in 2025, $8.7 billion market) and a second program in Macular Edema (Phase 1 in 2026, $9.6 billion market), BIOPHTA is currently targeting the two leading causes of blindness.